Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Assets Average (2016 - 2026)

Anika Therapeutics has reported Assets Average over the past 16 years, most recently at $184.8 million for Q1 2026.

  • Quarterly Assets Average fell 6.02% to $184.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $184.8 million through Mar 2026, down 6.02% year-over-year, with the annual reading at $196.5 million for FY2025, 16.98% down from the prior year.
  • Assets Average was $184.8 million for Q1 2026 at Anika Therapeutics, down from $189.9 million in the prior quarter.
  • Over five years, Assets Average peaked at $350.9 million in Q3 2022 and troughed at $184.8 million in Q1 2026.
  • The 5-year median for Assets Average is $267.2 million (2024), against an average of $273.1 million.
  • Year-over-year, Assets Average decreased 0.23% in 2023 and then dropped 28.14% in 2025.
  • A 5-year view of Assets Average shows it stood at $348.4 million in 2022, then dropped by 14.07% to $299.4 million in 2023, then fell by 27.5% to $217.1 million in 2024, then fell by 12.54% to $189.9 million in 2025, then decreased by 2.65% to $184.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Assets Average are $184.8 million (Q1 2026), $189.9 million (Q4 2025), and $188.6 million (Q3 2025).